<DOC>
	<DOCNO>NCT02655770</DOCNO>
	<brief_summary>The purpose study determine whether liraglutide GLP-1 analogue effective treatment diastolic dysfunction type 2 diabetes patient analyzed cardiac MRI . Secondary treatment effect perfusion heart cardiac-MRI .</brief_summary>
	<brief_title>Effect Liraglutide Diastolic Dysfunction Cardiac MRI Type 2 Diabetes Patients</brief_title>
	<detailed_description>Aim : To test treatment liraglutide GLP-1 analogue 18 week improve diastolic performance type 2 diabetes ( DM2 ) patient diastolic dysfunction , compare placebo . Furthermore , analyze cardiac MRI index fibrosis effect myocardial perfusion . The investigator find especially diastolic dysfunction interest , highly overrepresented DM2 patient treatment exists . Glucagon-like peptide 1 analogue could possible treatment agent , increase energy level myocardium . No previous study test effect treatment glucagon-like peptide 1 analogue diastolic dysfunction . Design : A randomised double-blinded placebo-controlled clinical trial . Sample size : 40 patient , 20 group . The superior inter-study reproducibility result considerably low calculated sample size ( reduction 55 % 93 % ) require cardiac MR compare echocardiography show clinically relevant change . Power calculation show 30 patient need form primary outcome , allow dropout investigator choose include 40 patient . Intervention : After randomization , patient treat placebo liraglutide ( 1.8 mg s.c. daily ) . Total treatment period 18 week . A cardiac MRI scan echocardiography preform baseline 18 week .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Liraglutide</mesh_term>
	<criteria>Male female patient fully capable informed consent Informed consent Age 1880 year ( year inclusive ) T2DM diagnose least 3 month prior visit 0 NYHA class IIII visit 0 E/e* ≥ 9 e* ( lateral ) ≤10 cm/sec , LVEF &gt; 50 % LVEDV/BSA &lt; 97 ml/m2 Stable heart medication 6 week prior randomisation Stable antidiabetic treatment 30 day prior randomisation T2DM must either treat one oral antidiabetic drug treat human NPHinsulin longacting insulin analogue , alone combination oral drug Lack consent . NYHA class IV Type 1 diabetes mellitus Incretinbased therapy ( GLP1 receptor agonist ; exenatide , liraglutide DPPIV inhibitor ) within 30 day prior randomisation ( visit 1 ) Glitazon therapy within 30 day prior randomisation ( visit 1 ) Hypertension inadequate blood pressure control : Systolic blood pressure &gt; 140 mmHg and/or diastolic blood pressure &gt; 85 mmHg* Supine systolic blood pressure &lt; 85 mmHg measure visit 0 Significant valvular heart disease Hypertrophic cardiomyopathy , ARVC/D , noncompaction amyloidosis Myocardial infarction , unstable angina , angina exertion ( ≥CCS class 2 ) coronary revascularization within 3 month prior randomisation ( visit 1 ) Hospitalisation due incompensated heart disease within 30 day randomisation ( visit 1 ) HbA1c &gt; 10 % visit 0 eGFR &lt; 60 ml/min/1,73 m2 visit 0 Liver disease aspartate aminotransferase/alanine aminotransferase &gt; 3 time upper limit normal measure visit 0** Hypokalaemia ( Ppotassium &lt; 3.5 mmol/L ) hyperkalaemia ( Ppotassium &gt; 5.5 mmol/L ) measure visit 0** Anaemia ( haemoglobin &lt; 6.5 mmol/L ) measure visit 0** Conditions may associate change marker fibroses collagen turnover ( eg . ongoing active rheumatological disease require antiinflammatory agent , immunosuppression , pulmonary fibrosis , active cancer ) Prolonged use ( &gt; 2 week ) glucocorticoid NSAIDs within 2 week prior visit 0 Women childbearing potential acceptable contraception . See . Pregnant breastfeed woman Cancer ( except basal cell skin cancer squamous cell skin cancer ) unless complete remission ≥ 5 year Alcohol/drug abuse Chronic previous acute pancreatitis History thyroid adenoma carcinoma Inflammatory bowel disease Clinical sign diabetic gastroparesis ICD/pacemaker contraindication MRI scan Severe claustrophobia Atrial fibrillation Contraindications glycopyrrolate : closedangle glaucoma , prostate hyperplasia , tachycardia , bladder atony , cardia insufficiency , noncongenital pylorus stenosis gastroparesis Known suspect hypersensitivity trial product relate product Current participation clinical intervention trial Receipt investigational drug 30 day prior visit 0 Other concominant disease treatment accord investigator 's assessment make patient unsuitable participation study Measured twice visit 0 . In case elevation , ambulatory ( 24hour ) blood pressure perform , result conclusive Measured visit 0 possibility one repeat analysis within week , last measure value conclusive .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>